Pds Biotechnology Corporation Stock Price, News & Analysis

PDS Biotechnology Corporation (Nasdaq: PDSB) will present at the LD Micro Main Event XV on October 26, 2022, at 4:30 PM PDT in Beverly Hills, California. The company focuses on targeted immunotherapies for cancer and infectious diseases through its Versamune® and Infectimune™ technology platforms. The lead candidate, PDS0101, shows promise in reducing tumors in HPV-positive cancers. Interested parties can access the presentation via a livestream.

PDS Biotechnology Corporation (Nasdaq: PDSB) announces the acceptance of an abstract detailing preclinical studies of its oncology products, PDS0102 and PDS0103, for presentation at the AACR Special Conference on Tumor Immunology and Immunotherapy 2022 in Boston from October 21-24, 2022. The abstract highlights the use of the Versamune® platform to target cancers like acute myeloid leukemia, prostate cancer, and breast cancer. The company aims to address multiple cancers with its innovative immunotherapies.

PDS Biotechnology Corporation (Nasdaq: PDSB) announced it will host a Head and Neck Cancer Key Opinion Leader Roundtable on October 26, 2022. The event aims to discuss the treatment of head and neck cancer, centering on PDS0101, the company’s leading product candidate that targets HPV-positive cancers. Moderated by Dr. Lauren Wood, the roundtable will feature insights from renowned oncologists. Registration is now open, and a live webcast will be available on their investor relations website.

PDS Biotechnology Corporation (PDSB) announced promising interim data from its Phase 2 trial of PDS0101-based therapy for advanced HPV-positive cancers. Notably, 66% of HPV 16-positive checkpoint inhibitor refractory patients survived at a median follow-up of 16 months, a significant improvement over the historical survival of 3-4 months. The trial, conducted at the National Cancer Institute, also highlighted a manageable safety profile, with 48% experiencing Grade 3 adverse events. The results underscore the potential of this therapy in a patient population with limited treatment options.

PDS Biotechnology Corporation (PDSB) announced the grant of nonstatutory stock options to Rory Cullinane, Vice President of Quality Assurance, for 70,000 shares at an exercise price of $3.62, the closing stock price on October 5, 2022. The options are part of PDSB’s 2019 Inducement Plan and will vest over four years, with one-quarter vesting after the first year. PDSB is focused on developing targeted immunotherapies for cancer and infectious diseases using its proprietary technology platforms, Versamune® and Infectimune™.

PDS Biotechnology Corporation (Nasdaq: PDSB) announced acceptance of two abstracts for presentation at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on November 8-12, 2022. The studies focus on PDS0101, their lead candidate targeting HPV-expressing cancers. One study investigates PDS0101 combined with standard chemoradiotherapy for cervical cancer, while the other examines a triple combination therapy for HPV16-associated cancers. The research highlights the potential of PDS0101 and the Versamune technology in treating underserved cancer indications.

PDS Biotechnology Corporation (Nasdaq: PDSB) announced the successful completion of an End-of-Phase 2 meeting with the FDA regarding PDS0101, in combination with Merck's KEYTRUDA®, for treating HPV16-positive head and neck cancer. FDA guidance paves the way for a Biologics License Application. Earlier, the FDA granted Fast Track designation for this combination, expediting its review process. PDS0101 has shown promising interim results, with 77% of patients stabilizing or shrinking tumors. This leads to an anticipated quicker transition into registrational trials.

PDS Biotechnology Corporation (Nasdaq: PDSB) announced the granting of nonstatutory stock options to key personnel as an inducement for their employment. Amber King received options for 5,000 shares, Charliene Casey for 12,000 shares, and David Schaaf for 70,000 shares, with an exercise price of $3.18, equal to the stock's closing price on September 22, 2022. The options will vest over four years, subject to continued employment. PDSB is focused on developing targeted immunotherapies for cancer and infectious diseases, utilizing its proprietary Versamune and Infectimune technology platforms.

PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company, announces that Dr. Frank Bedu-Addo, President and CEO, will participate in a panel at Cantor Fitzgerald’s Oncology & HemOnc Conference on September 28, 2022, at 1:45 PM EDT. The panel will focus on trends and challenges in immuno-oncology. PDS Biotech is developing targeted immunotherapies based on its Versamune® and Infectimune™ technology platforms, showing potential in treating HPV16-associated cancers and producing robust T cell responses.